Treating epithelial ovarian cancer by targeting folate receptor alpha with Mirvetuximab Soravtansine-gynx
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on January 26th, 2024
|
Epithelial ovarian cancer stands as the most lethal gynecologic neoplasm, with platinum-based chemotherapy demonstrating proven efficacy. However, in instances of relapse, these tumors develop resistance to platinum-based treatments. Notably, these tumors exhibit an abnormally elevated expression of folate receptor alpha (FRa). Addressing this, Mirvetuximab Soravtansine-gynx, an antibody specifically targeting FRa and conjugated to maytansinoid DM4, which acts on the cell's tubulin, has emerged. A recent study, exploring the impact of Mirvetuximab Soravtansine-gynx on epithelial ovarian cancer, has published its findings in the New England Journal of Medicine.
The research involved 453 patients diagnosed with ovarian cancer, who had undergone prior platinum-based chemotherapy and experienced disease progression within the preceding 3 to 6 months. Folate receptor alpha expression was quantified using the VENTANA FOLR1 (FOLR1-2.1) RxDx assay, with inclusion criteria requiring over 75% of tumor cells to exhibit strong expression. Participants were randomly assigned to receive treatment with either Mirvetuximab Soravtansine-gynx or the physician's choice of standard chemotherapy, including Paclitaxel, Doxorubicin, or Topotecan. Mirvetuximab Soravtansine-gynx was administered intravenously at a dosage of 6 mg per kilogram of body weight every 3 weeks. By the end of the study, results indicated that Mirvetuximab Soravtansine-gynx led to tumor shrinkage in 42.3% of patients, a significant improvement compared to the 15.9% observed in the standard chemotherapy group. Additionally, the researchers found that the intravenous usage of Mirvetuximab Soravtansine-gynx reduced the risk of death by 33%. Beyond enhanced clinical outcomes, the researchers noted that Mirvetuximab Soravtansine-gynx was associated with fewer adverse effects compared to standard chemotherapy.
The research involved 453 patients diagnosed with ovarian cancer, who had undergone prior platinum-based chemotherapy and experienced disease progression within the preceding 3 to 6 months. Folate receptor alpha expression was quantified using the VENTANA FOLR1 (FOLR1-2.1) RxDx assay, with inclusion criteria requiring over 75% of tumor cells to exhibit strong expression. Participants were randomly assigned to receive treatment with either Mirvetuximab Soravtansine-gynx or the physician's choice of standard chemotherapy, including Paclitaxel, Doxorubicin, or Topotecan. Mirvetuximab Soravtansine-gynx was administered intravenously at a dosage of 6 mg per kilogram of body weight every 3 weeks. By the end of the study, results indicated that Mirvetuximab Soravtansine-gynx led to tumor shrinkage in 42.3% of patients, a significant improvement compared to the 15.9% observed in the standard chemotherapy group. Additionally, the researchers found that the intravenous usage of Mirvetuximab Soravtansine-gynx reduced the risk of death by 33%. Beyond enhanced clinical outcomes, the researchers noted that Mirvetuximab Soravtansine-gynx was associated with fewer adverse effects compared to standard chemotherapy.